Chemotherapy naive
WebNov 3, 2024 · Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration ... WebChemotherapy naïve men with metastatic castration resistant prostate cancer and low baseline prostate specific antigen irrespective of disease burden may benefit from …
Chemotherapy naive
Did you know?
WebSep 30, 2014 · ASCO has just released a new set of provisional guidance (a “provisional clinical opinion” or PCO) on the second-line treatment of men with chemotherapy-naive, castration-resistant prostate cancer (CRPC), i.e., men who are progressing on initial androgen deprivation therapy (ADT or “hormone” therapy) but who haven’t had docetaxel … WebJun 1, 2015 · The term naïve patient refers to two specific categories: i) patients with no previous therapeutic exposure to originator (“primary naïve”), and ii) patients with previous exposure to the originator but with a wash-out period of time adequately long based on the judgment of the clinician (“secondary naïve”) [7]. 3.
WebPatients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs ≥1%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under … WebOct 14, 2024 · Background Anxiety, nausea and vomiting are common side effects suffered by paediatric patients receiving chemotherapy. Emerging evidence supports the efficacy of immersive virtual reality (IVR) on improving anxiety and distress symptoms including nausea and vomiting among this vulnerable group. This trial aims to assess the feasibility and …
WebMay 28, 2024 · Conclusions: Treatment with the combination of amivantamab and lazertinib yielded responses in 36% of chemotherapy-naïve pts who progressed on osi. Among these pts, genetic EGFR and MET-based biomarkers of resistance identified a subgroup of pts more likely to respond to amivantamab and lazertinib, although additional pts lacking … WebApr 1, 2024 · Activity in HER2-low mBC would define a newly targetable patient population, and T-DXd may be a potential treatment option for patients with hormone receptor-positive and HER2-low mBC who are chemotherapy-naive, had prior chemotherapy, or who failed endocrine-therapy and patients with HER2-low TNBC.
WebThis study aimed to assess the efficacy and safety of osimertinib in elderly chemotherapy-naive patients with NSCLC harboring sensitive EGFR mutations. Patients and Methods: We assessed the clinical effects of osimertinib as a first-line treatment for elderly NSCLC patients (≥ 75 years of age) with an exon 19 deletion or exon 21 L858R ...
WebMar 9, 2024 · Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. bmtcbus.comWebSep 30, 2014 · ASCO has just released a new set of provisional guidance (a “provisional clinical opinion” or PCO) on the second-line treatment of men with chemotherapy-naive, … bmtc big circleWebMar 14, 2024 · Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), 514 patients with treatment-naïve advanced ESCC were randomized (1:1) to receive toripalimab or placebo in combination with paclitaxel plus … cleverinWebOct 5, 2024 · Shu CA, Goto K, Ohe Y, et al. Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): preliminary results from CHRYSALIS-2. bmtc building koramangala income tax officeWebMar 9, 2024 · Kobayashi T, Terada N, Kimura T, Matsubara N, Murakami K, Mori K, et al. Sequential use of androgen receptor axis-targeted agents in chemotherapy-naive … bmtc buildingWebSep 30, 2024 · ACIS was a randomised, placebo-controlled, double-blind, phase 3 study of patients with chemotherapy-naive mCRPC receiving ongoing androgen deprivation therapy, done at 167 hospitals in 17 countries, including sites in the USA, Canada, Mexico, Spain, Italy, Russia, Belgium, France, the UK, the Netherlands, Germany, the Asia … clever in asu prepWebSep 21, 2024 · Among 45 osimertinib-relapsed, chemotherapy-naïve patients, the combination of amivantamab and lazertinib resulted in a 36 percent ORR (95 percent CI, … clever in birmingham